Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Suzhou 4B Technologies Closes $14 Million Pre-B Financing for Neuro Drugs

publication date: Dec 14, 2022

Suzhou 4B Technologies closed a $14 million Series Pre-B financing led by Fortune Capital to advance its portfolio of nine novel candidates for neurodegenerative diseases and neurological injuries. Founded in 2017, the company’s lead asset is aimed at treating amyotrophic lateral sclerosis and a rare condition. neuromyelitis optica.  Other products address acute optic nerve injury and a second ALS candidate co-developed with Peking University Third Hospital. 4B develops drugs through its own research and it partnership with outside pharmas and Tsinghua University. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here